Anastrozole vs Exemestane: Which AI Should Men on TRT or Cycle Use?

Anastrozole (Arimidex) and exemestane (Aromasin) are the two aromatase inhibitors most commonly used in men on testosterone replacement therapy or anabolic steroid cycles. Both were developed for oestrogen receptor positive breast cancer in postmenopausal women, and almost all rigorous comparative data come from that population. Their use in men is off-label.

Anastrozole is a non-steroidal, reversible competitive inhibitor of aromatase. It binds the enzyme without modifying it. When anastrozole is cleared, aromatase function returns rapidly.

Exemestane is a steroidal, irreversible "suicide" inhibitor. Each exemestane molecule that binds aromatase permanently inactivates it. Aromatase activity only recovers as the body synthesises new enzyme, typically over 2 to 3 days after exemestane is discontinued.

The choice between the two in men is dominated by mechanistic logic and tradition rather than head-to-head clinical evidence. There are no randomised trials comparing anastrozole and exemestane in TRT-using men or in anabolic steroid users. The comparison below is based on the pharmacology of each agent, breast cancer literature, the small body of male-only AI dosing data, and observed practice in TRT and bodybuilding communities.

Mechanism:

• Anastrozole: non-steroidal, reversible competitive inhibition. Like a key that fits the lock and then falls out.
• Exemestane: steroidal, irreversible "suicide" inhibition. The molecule binds aromatase covalently and inactivates it for the life of that enzyme molecule.

Pharmacology of recovery:

• Anastrozole: when plasma anastrozole falls, aromatase recovers in hours. This makes anastrozole highly responsive to dose changes but also susceptible to oestradiol rebound if dosing is missed or stopped abruptly.
• Exemestane: aromatase only recovers as new enzyme is synthesised. Estradiol levels return more slowly after exemestane stops, typically over 2 to 3 days.

Half-life:

• Anastrozole: approximately 50 hours. Standard female breast cancer dose is 1 mg daily; in men with high oestradiol on TRT, doses of 0.25 to 0.5 mg two to three times per week are typical.
• Exemestane: approximately 24 hours, but functional duration is longer because the enzyme inactivation persists. Standard breast cancer dose is 25 mg daily; in men, doses of 12.5 mg every other day or three times per week are typical.

Dosing forgiveness:

• Anastrozole requires consistent dosing to maintain stable oestradiol. A missed dose can cause measurable estradiol rebound within 24 to 48 hours.
• Exemestane is more dose-forgiving on a day-to-day basis because the enzyme remains inactivated. Most users find weekly dose schedules less prone to oscillating oestradiol.

Androgenic activity:

• Anastrozole: no androgenic activity. It is structurally a triazole.
• Exemestane: weakly androgenic. It is structurally a 6-methylenandrostadien-3,17-dione, a steroidal molecule that retains some androgen receptor affinity. This is the basis of the "exemestane is more anabolic" claim, but the magnitude is small and clinically marginal at typical AI doses.

Estrogen rebound risk on discontinuation:

• Anastrozole: estradiol can rise rapidly within 24 to 48 hours of stopping. This is a known issue in breast cancer treatment cessation.
• Exemestane: estradiol rises more gradually as new aromatase is synthesised, over 2 to 5 days.

Effect on IGF-1 and SHBG:

• Both agents raise testosterone in men with intact HPG axes by removing oestradiol feedback on the hypothalamus and pituitary. In Leder 2004 (PMID 15001605), anastrozole 1 mg/day raised total testosterone from 343 to 572 ng/dL in elderly hypogonadal men over 12 weeks.
• Exemestane in men: smaller and less rigorous trials suggest similar effects, but no direct comparison exists.

Lipid impact:

• The claim that exemestane has a more favourable lipid profile than anastrozole in men is widely repeated in bodybuilding spaces but is not well-supported by male-specific RCT data. Breast cancer trials in women (TEAM, others) show variable lipid effects. Leder 2004 reported neutral-to-mildly-negative HDL effects on anastrozole in elderly hypogonadal men. No comparable male trial exists for exemestane.

Bone density:

• Both AIs reduce bone mineral density with chronic use when estradiol is suppressed below the male physiological range. This is well-documented in breast cancer treatment populations and is biologically plausible in men. The Burnett-Bowie 2009 trial of anastrozole in older hypogonadal men over 12 months showed no improvement in body composition despite normalised testosterone, with broader concerns about long-term estradiol suppression in men.

Cost and availability:

• Anastrozole: widely available as a cheap generic. The most commonly prescribed AI in male TRT contexts.
• Exemestane: also generic and widely available, though slightly more expensive on average. Available from compounding pharmacies and most online pharmacies.

Use anastrozole if:

• You want fast, responsive dose control. The reversible mechanism means each dose change feeds back quickly into your bloodwork.
• You are comfortable with consistent dosing (every other day or three times per week) and are not prone to missing doses.
• You are starting at low doses (0.125 to 0.25 mg) and titrating up. Anastrozole is easier to "feel out" because the effect of a dose change is rapid.
• Your TRT prescriber is more familiar with anastrozole, which is the more commonly prescribed AI in male HRT contexts.

Use exemestane if:

• You prefer fewer dosing decisions. The irreversible mechanism means missed doses are less disruptive.
• You are concerned about estradiol rebound when stopping the AI (e.g., during a cycle taper or cruise).
• You suspect anastrozole is causing lipid changes (an unproven but theoretical advantage of exemestane).
• You want the marginal androgenic effect of the molecule itself (an effect that is biologically real but small at AI doses).

Use neither if:

• You are asymptomatic. The most common AI use mistake in men is treating a number rather than a symptom complex.
• Your problem is gynecomastia tissue specifically. A SERM (raloxifene or tamoxifen) is the targeted intervention; AIs treat systemic estradiol but do not directly block the breast estrogen receptor.
• You are mid-cycle and only have a few weeks left. Crashing estradiol at the end of a cycle compounds PCT difficulty.

Starting doses in men (TRT or cycle context):

• Anastrozole: 0.125 to 0.25 mg twice to three times weekly. Adjust based on bloodwork at 4 to 6 weeks.
• Exemestane: 12.5 mg every other day or three times weekly. Adjust based on bloodwork at 4 to 6 weeks.

Stop and reassess if:

• Joint pain, dry skin, low libido, anhedonia, or insomnia emerge (signs of crashed estradiol).
• HDL drops noticeably on follow-up bloodwork.
• Your T:E2 ratio rises above 40 with any deficiency symptoms.